A pretty good trading statement released and plenty of "points" to drive this forward.Interims out on the 21st and a current spread of 14.25/13.5

Where to next ?

LOL!

[Edited by moderator to reduce font size as it was corrupting the thread format.]

Telegraph recomendation http://www.telegraph.co.uk/money/main.jhtml?xml=%2Fmoney%2F2003%2F04%2F27%2Fccmm27.xml
Shot in the arm for Medisys
Medisys, the healthcare company, is poised to launch two key products in the US, marking a pivotal stage in its development.
Its Futura safety syringe, which helps prevent needlestick injury and the spread of blood-born infections, is expected to be approved by Smiths Group, its US distribution partner, this summer, triggering a $2m milestone payment. Medisys is also ready to launch Flight, a blood glucose monitoring system for diabetics.
The company seems close to shrugging off its reputation for over-promising and under-delivering. It has also appointed a new chief executive, David Conn, whose sales and marketing experience with big pharmaceutical companies, will help steer the group towards recovery. At 12.75p the shares look cheap. Buy.

Give it a rest Clive .

RNS Number:2545K
Medisys PLC
23 April 2003


Embargoed until 0701 23 April 2003

Medisys PLC
("Medisys" or "the Company")

AGM Statement

At the Annual General Meeting, which is scheduled to take place later today, Mr
Derek Ablett, Chairman, will make the following comments:

Trading Update

Overall, trading for the six months ended 31 March 2003 was much improved on the
previous year and is in line with our expectations.

- Revenues from product sales, excluding one time license fees,
exceeded #20 million in the period, compared to #17.7 million in the previous
year. Major contributors to the increase were sales of QuickTek (#2.6 million)
and the Lark safety scalpel (#1.0 million).

- Gross margins on product sales increased to approximately 37%
compared to 33% in the previous year.

- The Company is on target to achieve the expected annual savings of
approximately #4 million in selling, distribution and administration expenses
identified at the time of the preliminary results announcement in December 2002.

- Research and development spend in the period was approximately #1
million higher than expected due to the additional expenditure required to
resolve the issues with the Futura Safety syringe and also on final design
optimisation on the Flight product.

- As expected, the Company's level of operating cash burn and capital
expenditure have declined significantly over the prior year period.

- The Board remains confident that the current cash resources available
to the Company, including the #5 million line of credit, are sufficient to
finance the business through to the point where it becomes cash generative.

Product Update

3ml Futura Safety Syringe

The minor dimensional changes required to eliminate the adverse characteristic
identified in quality assurance testing late last year have now been made to the
Futura Safety Syringe. The revised product has met the product's design and
performance specification and has successfully completed the Company's own
stringent pre-launch quality testing. Based upon a continuing assessment of
market preferences a minor enhancement has recently been made to the product.
The Company anticipates that production batches of product incorporating this
enhancement will be shipped to Smiths by mid May. Immediately following its
acceptance of the product, Smiths is scheduled to commence the launch by mid
2003.

1ml Futura Safety Syringe

As previously announced, the Company's current focus is on launching the 3ml
safety syringe. Although the development of the 1ml syringe is essentially
complete, the Board does not intend to launch it until the 3ml has been launched
and Smiths is able to provide its assessment of market demand for the 1ml
product based upon market uptake of the 3ml.

QuickTek

Sales of the QuickTek product increased rapidly during the first half. GEMCO,
our marketing partner, have now placed approximately 45,000 QuickTek meters in
the market through their mail order sales channels and we are already seeing a
significant increase in strip revenue. During the current quarter we anticipate
some softness in QuickTek strip sales as GEMCO has informed us that it will be
re-balancing its inventory levels. However, we believe that this is a short-term
phenomenon and that we should see sales growth resume thereafter.

Advance

Shipments of the Advance system to GEMCO commenced in December 2002 and have
grown steadily since then. Advance is also being sold into the mail order
segment, although it is positioned at a higher price point than QuickTek due to
its higher specification. Sales in the four months to the end of March 2003 were
approximately #0.5 million, including shipment of initial inventory quantities
to GEMCO, and the Board is confident that significant sales growth will be
achieved in the coming months.

Flight

As announced on 1 April 2003, The Company recently received FDA approval to
market the Flight disposable blood glucose monitoring system. The final
pre-production Flight units are now being assembled by our manufacturing
partner, Polyflex Limited. Upon successful completion of final testing we will
commence manufacturing production volumes of the product and it will be launched
with our US retail partner by mid 2003.

Spear

Development of the Spear product is progressing well and the Board believes that
it will be launched in the market later this year. Spear is based on the
Company's proprietary biosensor utilising capillary fill technology which
enables it to use a 50% smaller blood sample. This strip will be reverse
compatible with the Advance meter allowing it to be used with the existing
installed base of Advance meters. The Board also believes that there will be
other additional opportunities to market the Spear product within the retail
market segment.

Board

The Company has also announced separately today two important senior management
appointments. Mr David Conn has been appointed Chief Executive Officer and Dr
David Wong will assume the role of Chairman following today's Annual General
Meeting. Mr Derek Ablett will remain as a non-executive director of the Company.

- Ends -

Enquiries:

Medisys PLC 020 7563 5200
David Conn, Chief Operating Officer
Michael Barry, Chief Financial Officer

Weber Shandwick Square Mile 020 7067 0700
Kevin Smith/Susanne Walker




This information is provided by RNS
The company news service from the London Stock Exchange

END
AGMILFEASLIFFIV

See Fidelity feel confident by upping their stake.

LOL !

Positive candidate (9 May 2003) [Auto] Help
Has fallen 83% since the peak on 1 Feb 2002 at 95.50. Has broken the ceiling of the falling trend, which indicates a slower initial falling rate. The volume balance is positive and strengthens the stock in the short term. The stock has broken up through the resistance at p 15.00. This predicts a further rise. In case of negative reactions, there will now be support at p 15.00. High risk with an average difference between the lowest and the highest price of the month of 71%.

Another great performance by MDY today.

yet another great performance by MDY today.

See there was a mention in the FT that MDY has " turned the corner" and shows positive signs of recovery.

"Stars and dogs: Telecoms in focus
By our markets staff
FT.com site; May 16, 2003


Telecommunications companies were in the spotlight this week with Cable and Wireless taking the crown of the best performer while Marconi plummeted in its last week of trading.

Medisys, the medical products maker, rose 24.2 per cent to 20.5p this week, its highest point since late September, as dealers reassessed the companys long-term prospects. Delays to the delivery of its Futura safety syringe made 2002 a write-off but this year major investors like Fidelity have snapped up shares.

The imminent launch of Futura this summer and control over its cash burn rate have made the Medisys story more attractive, but others point to its high valuation and risks to the developing syringe market as reasons to be cautious."

Harsh treatment from the market for MDY this morning considering the lack of nasty surprises. The successful launch of new products could really push this one forward now cash burn seems to be under control.

I take a trading interest in these on occasions

Edmond Jackson: Medisys cannot escape volatility
21 May 2003


Following a sharp rise in the share price of medical safety and diagnostics group Medisys, it has declared 'significantly improved' financial performance today in its interim results.

Expect a trading statement later this month.Could be a good buying opportunity at this level.

Can somebody explain why,given all of the recent positive news about Medisys,(the roll out of products and the deal with Wal Mart)coupled with market buys exceeding sells on most days,the share price appears to have been driven artificially lower.Today's early price loss is a prime example of this.

I think like myself most investors run a stop loss medisys ran through mine and i sold them off looking at the charts the sellers are outnumbering the buyers as more stop losses are breached.But do not dispair a new buy signal is forming.I think anything around 17 to 20 is a possible support.

Well looking at the activity today I think we can safely say that the support well and truly kicked in.I am looking to add on Monday as I see a rise back to 25p on the cards in the run up to the trading statement.

What date can we expect the trading update ?

Returning to my comments of 12th Sept.Can anybody make sense of today's drop in price given the buy/sell ratio.This following on from a 0.75p rise yesterday when sells far outweighed buys.Price manipulation?

You must look at the bigger picture. Sometimes you need to look one or more days before and after to get the true picture. Some days MDY will drop with more buys than sells, the next day it will go up with more sells than buys. Average the two days out the price stays the same with buys and sells equal.

Another thing to remember is the MM's will make money if the price goes up or down so the will manipulate the price.